University of Texas's MD Anderson Cancer: Metabolic Inhibitor IACS-6274 Shows Early Antitumor Effects in Underserved Patients With Advanced Cancers
May 19, 2021
May 19, 2021
HOUSTON, Texas, May 19 (TNSRes) -- The University of Texas's MD Anderson Cancer Center issued the following news release:
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial. Interim results of the study will be presented at the 2021 American S . . .
The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center's Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial. Interim results of the study will be presented at the 2021 American S . . .